Here, we describe the ability of LOXO-292 to overcome acquired RET kinase domain mutations preclinically and in two patients with RET-altered cancers, one with acquired gatekeeper mutation resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results